Clinical Trial Update: A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer

View source ↗

Summary

This ClinicalTrials.gov study aims to learn about the real-world safety of darolutamide in participants with metastatic hormone-sensitive prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer

Drugs mentioned

• Darolutamide (darolutamide)

Snippet

Sponsor: Bayer | Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Status: ACTIVE_NOT_RECRUITING